SMAD4 and neoplasm: As SMAD4 reduces CXCL1 expression by decreasing inhibitor of NF-κB kinase β (IKKβ) activity and affecting glycogen synthase kinase-3β (GSK-3β), a decrease in SMAD4 expression in a tumor cell increases CXCL1 expression.